Mitochon Pharmaceuticals, Inc. Email Format

Biotechnology ResearchPennsylvania, United States2-10 Employees

Mitochon Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies that target mitochondrial function to address serious diseases with unmet medical needs. Its programs concentrate on neurodegenerative disorders, including Huntington’s disease, multiple sclerosis, ALS, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. The company proposes that mitochondrial dysfunction—leading to oxidative stress, reduced ATP production, calcium overload, and aging-related decline—underpins these conditions and seeks to correct it with brain-penetrant, oral therapies.

Based in Blue Bell, Pennsylvania, the company operates as a small team pursuing clinically staged drug development. Its work sits within the biotechnology research sector and focuses on mitochondrial-targeted compounds as potential disease-modifying options. In recent developments, the FDA granted Orphan Drug Designation for MP-101 for Huntington’s Disease.

Get verified Mitochon Pharmaceuticals, Inc. emails free

Company overview Employee directory